Back

Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial

27 August 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Congress committee e-posters choice in heart failure Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Professor Michele Senni

Papa Giovanni XXIII Hospital, Bergamo (Italy)

46 More presentations in this session

Presentation thumbnail
Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes
Doctor A. Sharma (Montreal, CA)
Abstract Slides
Presentation thumbnail
SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis
Doctor V. Razuk (New York City, US)
Abstract Slides
Presentation thumbnail
Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis
Doctor G. Steiner-Gager (Vienna, AT)
Abstract Slides
Presentation thumbnail
Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin
Doctor J. Kolwelter (Erlangen, DE)
Abstract Slides
Presentation thumbnail
Empagliflozin reduces TNFa-induced reactive oxygen species through inhibition of the human endothelial Na+/H+ exchanger 1
Doctor L. Uthman (Nijmegen, NL)
Abstract Slides

Access the full session

Session thumbnail
Congress committee e-posters choice in heart failure

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Clinical characteristics and long-term prognosis of patients with heart failure with reduced, mildly reduced, and preserved left ventricular ejection fraction secondary to Chagas cardiomyopathy
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources